Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats

Journal of Hypertension

Volumn 17, Issue 6, 1999, Pages 769-776

  De Sotomayor, María Alvarez ^a   Pérez Guerrero, Concepción ^a   Herrera, Maria Dolores ^a   Marhuenda, Elisa ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Endothelium; Rat isolated aorta; SHR; Simvastatin

Indexed keywords

ACETYLCHOLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; OUABAIN; PROSTAGLANDIN SYNTHASE; SIMVASTATIN; SODIUM CALCIUM EXCHANGE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENZYME INHIBITION; HYPERTENSION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

EID: 0033053946     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917060-00008     Document Type: Article

References (42)

1. 1 Ames RP. Hyperlipidemia in hypertension: causes and prevention. Am Heart J 1991; 122:1219-1224.
2. 2 Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxations in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
3. 3 Henry PD. Hyporlipidemic arterial dysfunction. Circulation 1990; 81:697-699.
4. 4 Macmahon SW, Macdonald GL, Blacket RB. Plasma lipoprotein levels in treated and untreated hypertensive men and women: the National Health Foundation of Australia Risk Factor Prevalence Study. Atherosclerosis 1985; 5:391-396.
5. 5 Laurenzim M, Mancini M, Menotti A, Stamler J, Stamler R, Trevisan M, et al. Multiple risk factors in hypertension: results from the Gubbio study. J Hypertens 1990; 8 (Suppl. 20):7-12.
6. 6 O'Donell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduces glomorural injury in Dahl salt-sensitive rats. Hypertension 1992; 20:651-658.
7. 7 Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30:968-974.
8. 8 Mauro VF, Macdonald JL. Simvastatin: a review of its pharmacology and clinical use. DICP 1991; 25:257-264.
9. 9 Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21:505-517.
10. 10 Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430.
11. 11 Soma MR, Parolini C, Donetti E, Fumagalli R, Paoletti R. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1995; 25 (Suppl. 4);S20-S24.
12. 12 Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, et al. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997; 281:1144-1153.
13. 13 Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348:1079-1082.
14. 14 Bravo L, Herrera MD, Marhuenda E, Perez-Guerrero C. Cardiovascular effects of lovastatin in normotensive and spontaneously hypertensive rats. Gen Pharmacol 1998; 30:331-336.
15. 15 Koga T, Takata Y, Kobayashi K, Takishita S, Yamashita Y, Fujishima M. Age and hypertension promote endothelium-dependent contractions to acetylcholine in the aorta of the rat. Hypertension 1989; 14:542-548.
16. 16 Lüsher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension 1992; 19:117-130.
17. 17 Lüsher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8:344-348.
18. 2-receptor antagonists inhibit endothelium-dependent contractions. Hypertension 1990; 15:699-703.
19. 19 Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21:929-933.
20. 20 Küng CF, Lüsher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995; 25:194-200.
21. 21 Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-Co A reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272:31725-31729.
22. 22 Stroes ES, Koomen HA, De Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346:467-471.
23. 23 O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-1130.
24. 24 Fukada Y, Takao T, Ohguro H, Yoshizawa T, Akino T, Shimonishi Y. Farnesylated gamma-subunit of photoreceptor G protein indispensable for GTP-binding. Nature 1990; 346:658-660.
25. 25 Finder JD, Litz JL, Blaskovich MA, McGuires TF, Quian Y, Hamilton AD, et al. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1β in vascular smooth muscle cells. J Biol Chem 1997; 272:13484-13488.
26. 26 Gil-Longo J, Dufour MN. Guillon G, Lugnier C. G proteins in aortic endothelial cells and bradykinin-induced formation of nitric oxide. Eur J Pharmacol 1993; 247:119-125.
27. 27 Flavahan NA, Vanhoutte PM. G-proteins and endothelial responses. Blood Vessels 1990; 27:218-229.
28. 28 Swales JD. Is there a cellular abnormality in hypertension? J Cardiovasc Pharmacol 1991; 18 (Suppl. 2):S39-S44.
29. + exchange activity in vascular smooth muscle cells of spontaneously hypertensive rats and possible involvement of protein kinase C. Clin Exp Pharmacol Physiol 1992; 19:171-176.
30. 30 Adragna NC, Canessa ML, Solomon H, Slater E, Tosteson DC. Red cell lithium-sodium counter transport and sodium-potassium co-transport in patients with essential hypertension. Hypertension 1982; 4:795-804.
31. 31 Bing RF, Heagerty AM, Swales JD. Membrane handling of calcium in essential hypertension. J Hypertens 1987; 5 (Suppl.):S29-S35.
32. 32 Marin J, Sánchez-Ferrer CF, Salaices M. Effects of ouabain on isolated cerebral and femoral arteries of the cat: a functional and biochemical study. Br J Pharmacol 1988; 93:43-52.
33. + exchange mediation in the ouabain-induced contraction in human placental vessels. Gen Pharmacol 1992; 23:439-444.
34. 34 Mulvany MJ. Changes in sodium pump activity and vascular contraction. J Hypertension 1985;3:429-436.
35. 35 Boulanger C, Hendrickson H, Lorenz RR, Vanhoutte PM. Release of different relaxing factors by cultured endothelial cells. Circ Res 1989; 64:1070-1078.
36. 36 Alonso MU, Salaices M, Sánchez-Ferrer CF, Hernández MC, Marin J. Predominant role for nitric oxide in the relaxation induced by acetylcholine in cat cerebral arteries. J Pharmacol Exp Ther 1992; 261:12-20.
37. 37 Sunano S, Tsuji A, Shimada T, Shimamura K. Comparison of the effects of sodium vanadate and ouabain of vascular smooth muscles of Wistar-Kyoto rats and stroke-prone spontaneously hypertensive rats. J Hypertens 1986; 4 (Suppl.3):S261-S262.
38. + -free solution in aorta from hypertensive rats. Am J Physiol 1986; 250:H612-H619.
39. 39 Sakai Y, Inazu M. Sodium pump activity and contractions of renal arteries from spontaneously hypertensive rats. Eur J Pharmacol 1991; 200:227-231.
40. 40 Ponte A, Sánchez-Ferrer CF, Hernández C, Alonso MJ, Marin J. Effect of ageing and hypertension on endothelial modulation of ouabain-induced contraction and sodium pump activity in the rat aorta. J Hypertens 1996; 14:705-712.
41. 2+ exchanger. FEBS Letters 1994; 343:151-154.
42. 42 Lijnen P, Hilde C, Fagard R, Staessen J, Amery A. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens 1994; 12:59-6.